User login
Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.
Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.
Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.
Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.
Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi: 10.1016/j.jaip.2021.11.034.
Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.
Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.
Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.
Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.
Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi: 10.1016/j.jaip.2021.11.034.
Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.
Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.
Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.
Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.
Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi: 10.1016/j.jaip.2021.11.034.